PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC MutationsX. Le, J. Wang, Y. Zhao et al.|Journal of Thoracic Oncology|2024Cited by 14